Leerink Swann reissued their market perform rating on shares of Gilead Sciences Inc. (NASDAQ:GILD) in a research note issued to investors on Tuesday morning. Leerink Swann currently has a $89.00 price objective on the biopharmaceutical company’s stock.

Other research analysts have also recently issued research reports about the stock. Piper Jaffray Cos. set a $108.00 price target on shares of Gilead Sciences and gave the company a buy rating in a research report on Sunday, August 21st. Cowen and Company set a $120.00 price target on shares of Gilead Sciences and gave the company a buy rating in a research report on Sunday, October 23rd. Maxim Group reissued a hold rating on shares of Gilead Sciences in a research report on Sunday, November 6th. Zacks Investment Research raised shares of Gilead Sciences from a strong sell rating to a hold rating in a research report on Monday, November 7th. Finally, Mizuho assumed coverage on shares of Gilead Sciences in a research report on Monday, November 7th. They set a buy rating and a $88.00 price target on the stock. Ten equities research analysts have rated the stock with a hold rating, nineteen have given a buy rating and two have issued a strong buy rating to the company. Gilead Sciences currently has a consensus rating of Buy and an average price target of $97.90.

Analyst Recommendations for Gilead Sciences (NASDAQ:GILD)

Gilead Sciences (NASDAQ:GILD) opened at 75.58 on Tuesday. The firm’s 50-day moving average is $75.03 and its 200-day moving average is $80.64. Gilead Sciences has a 52-week low of $71.39 and a 52-week high of $108.63. The stock has a market cap of $99.57 billion, a P/E ratio of 6.99 and a beta of 1.25.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Tuesday, November 1st. The biopharmaceutical company reported $2.75 earnings per share for the quarter, missing the consensus estimate of $2.87 by $0.12. The firm had revenue of $7.40 billion for the quarter, compared to analyst estimates of $7.47 billion. Gilead Sciences had a net margin of 47.74% and a return on equity of 100.57%. The company’s revenue was down 9.6% compared to the same quarter last year. During the same period in the previous year, the firm posted $3.22 EPS. Equities research analysts predict that Gilead Sciences will post $11.47 earnings per share for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, December 29th. Investors of record on Thursday, December 15th will be given a dividend of $0.47 per share. This represents a $1.88 dividend on an annualized basis and a yield of 2.49%. The ex-dividend date is Tuesday, December 13th. Gilead Sciences’s dividend payout ratio is presently 17.44%.

In related news, insider John C. Martin sold 100,000 shares of Gilead Sciences stock in a transaction dated Thursday, September 1st. The stock was sold at an average price of $77.48, for a total transaction of $7,748,000.00. Following the completion of the sale, the insider now owns 3,287,810 shares in the company, valued at approximately $254,739,518.80. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Kevin E. Lofton sold 3,500 shares of Gilead Sciences stock in a transaction dated Wednesday, August 24th. The stock was sold at an average price of $81.97, for a total value of $286,895.00. The disclosure for this sale can be found here. Corporate insiders own 1.40% of the company’s stock.

A number of hedge funds have recently bought and sold shares of GILD. Loomis Sayles & Co. L P boosted its stake in Gilead Sciences by 23.3% in the first quarter. Loomis Sayles & Co. L P now owns 1,591 shares of the biopharmaceutical company’s stock valued at $146,000 after buying an additional 301 shares during the period. Bogle Investment Management L P DE boosted its stake in Gilead Sciences by 29.7% in the first quarter. Bogle Investment Management L P DE now owns 128,318 shares of the biopharmaceutical company’s stock valued at $11,787,000 after buying an additional 29,400 shares during the period. Mariner Wealth Advisors LLC boosted its stake in Gilead Sciences by 14.7% in the first quarter. Mariner Wealth Advisors LLC now owns 47,450 shares of the biopharmaceutical company’s stock valued at $4,358,000 after buying an additional 6,092 shares during the period. Dodge & Cox boosted its stake in Gilead Sciences by 103.2% in the first quarter. Dodge & Cox now owns 7,620 shares of the biopharmaceutical company’s stock valued at $700,000 after buying an additional 3,870 shares during the period. Finally, Hancock Holding Co. boosted its stake in Gilead Sciences by 0.4% in the first quarter. Hancock Holding Co. now owns 25,718 shares of the biopharmaceutical company’s stock valued at $2,362,000 after buying an additional 110 shares during the period. Hedge funds and other institutional investors own 76.90% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines in areas of unmet medical need. The Company’s principal areas of focus include human immunodeficiency virus (HIV), liver diseases, such as chronic hepatitis C virus infection and chronic hepatitis B virus infection, cardiovascular, hematology/oncology and inflammation/respiratory.

5 Day Chart for NASDAQ:GILD

Receive News & Stock Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related stocks with our FREE daily email newsletter.